β¨ Medicines Distribution Consents
28 OCTOBER NEW ZEALAND GAZETTE 3201
Dated this 20th day of October 1993.
C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
go9113
Consent to the Distribution of Changed Medicines
Pursuant to section 24(5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Clarithromycin 125 mg/5 ml, | Granules for oral suspension | Abbott Laboratories Limited, Queenborough, Kent, Great Britain, Abbott Australasia Pty Limited, Kurnell, New South Wales, Australia and Abbott S.p.A., Campoverde de Aprilia, Latina, Italy | Klacid Paediatric Suspension |
| 250 mg/5 ml | |||
| Clarithromycin 500 mg | Powder for reconstitution for injection | le laboratoire Abbott France, Usine de lβIsle, Saint-Remy-Sur-Avre, France | Klacid I.V. |
| Botulinum Toxin type A 100 units/vial | Powder for reconstitution for IM injection | Adria S P Inc., Albuquerque, New Mexico, United States of America | Occulinum Injection |
| Ondansetron (as the hydrochloride dihydrate) 4 mg, 8 mg | Tablets | Glaxo Operations UK Limited, Barnard Castle, County Durham, Great Britain and Glaxo Operations UK Limited, Ware, Hertfordshire, Great Britain | Zofran |
| Ondansetron (as the hydrochloride dihydrate) 4 mg/2 ml, 8 mg/4 ml | Solution for IV and IM injection | Glaxo Operations UK Limited, Barnard Castle, County Durham, Great Britain | Zofran Injection |
| Salmeterol (as xinafoate) 25 mcg | Suspension (metered dose inhaler) | Glaxo Group Research Limited, Ware, Hertfordshire, Great Britain, Laboratoires Glaxo SA, Evreux, France and Glaxo New Zealand Limited, Palmerston North | Serevent Inhaler |
| Salmeterol (as xinafoate) 50 mcg | Rotadisks | Glaxo Group Research Limited, Ware, Hertfordshire, Great Britain and Laboratoires Glaxo SA, Evreux, France | Serevent |
Dated this 21st day of October 1993.
C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
go9114
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Botulinum Toxin type A 100 units/vial | Powder for reconstitution for IM injection | Adria S P Inc., Albuquerque, New Mexico, United States of America | Botox |
| Fleroxacin 400 mg/100 ml | Solution for infusion | F Hoffmann-La Roche Limited, Basle, Switzerland | Quinodis |
| Fleroxacin 200 mg, 400 mg | Tablets | F Hoffmann-La Roche Limited, Basle, Switzerland | Quinodis |
| Methadone hydrochloride 5 mg | Tablet | Douglas Pharmaceuticals Limited, Technical Division, Mount Roskill, Auckland | Pallidone |
| Note: Not to be marketed as substitutable for any other methadone hydrochloride product as if the two (2) products were bioequivalent. | |||
| Isosorbide dinitrate 5 mg | Tablet (sub-lingual) | Apotex Inc., Weston, Ontario, Canada | APO-ISDN |
| Paracetamol 500 mg, pseudoephedrine hydrochloride 30 mg, tripolidine hydrochloride 1.25 mg | Tablet | Wellcome Australia Limited, Cabarita, Sydney, New South Wales, Australia | Sudafed Plus |
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1993, No 156
NZLII —
NZ Gazette 1993, No 156
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare20 October 1993
Medicines Act, Distribution Consent, Changed Medicines, Pharmaceuticals
- C. Lovelace, Director-General of Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare21 October 1993
Medicines Act, Distribution Consent, New Medicines, Pharmaceuticals
- C. Lovelace, Director-General of Health